Center for Childhood Cancer Research

  • CCCR NewsletterCCCR Newsletter
  • FacebookFacebook
  • TwitterTwitter
  • Ways to Give
  • Home
  • About
    • Colket Translational Research Building
    • Abramson Cancer Center
    • Research Programs & Laboratories
    • Ways To Give
    • Donate Now
  • Research
    • Hematopoietic Malignancies
    • Brain Tumors
    • Neuroblastoma
    • Sarcoma
    • Survivorship
    • Behavioral Oncology
    • Developmental Therapeutics
  • Our Team
    • Leadership
    • Faculty
    • Research Administration
  • Training
    • Biomedical Graduate Groups
    • Clinical Fellowships
    • Cancer Center T32
    • Cancer Center K12
  • Clinical Trials
    • Protocol Search
  • News & Events
    • CCCR Newsletter
    • View Funding Opportunities
    • CCCR Publications from July 1st 2010 to June 30th 2011
    • CCCR-ALSF Symposium on Translational Oncology
  • Contact Us
    • Faculty
    • Research Administration
  • Skip to content
Home Research Hematopoietic Malignancies Susan Rheingold, MD
Susan Rheingold, MD
Susan Rheingold, MD

 

Hematopoietic Malignancies

  • A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
  • Folate Fortification and Survival of Children with Acute Lymphoblastic Leukemia.
  • Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium.
  • Skip to content
  • For Patients
  • For Doctors
Children's Hospital of Philadelphia Research Institute Logo
  • Log In
  • Site Map
  • Privacy
  • Terms

© The Children's Hospital of Philadelphia, All Rights Reserved.